0001498403 2024-12-31 0001498403 ifrs-full:RetainedEarningsMember 2024-12-31 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2024-12-31 0001498403 ifrs-full:CapitalReserveMember 2024-12-31 0001498403 ifrs-full:WarrantsMember 2024-12-31 0001498403 ifrs-full:SharePremiumMember 2024-12-31 0001498403 ifrs-full:IssuedCapitalMember 2024-12-31 0001498403 2025-01-01 2025-06-30 0001498403 ifrs-full:RetainedEarningsMember 2025-01-01 2025-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2025-01-01 2025-06-30 0001498403 ifrs-full:CapitalReserveMember 2025-01-01 2025-06-30 0001498403 ifrs-full:WarrantsMember 2025-01-01 2025-06-30 0001498403 ifrs-full:SharePremiumMember 2025-01-01 2025-06-30 0001498403 ifrs-full:IssuedCapitalMember 2025-01-01 2025-06-30 0001498403 2025-12-31 0001498403 ifrs-full:RetainedEarningsMember 2025-12-31 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2025-12-31 0001498403 ifrs-full:CapitalReserveMember 2025-12-31 0001498403 ifrs-full:WarrantsMember 2025-12-31 0001498403 ifrs-full:SharePremiumMember 2025-12-31 0001498403 ifrs-full:IssuedCapitalMember 2025-12-31 0001498403 2026-01-01 2026-06-30 0001498403 ifrs-full:RetainedEarningsMember 2026-01-01 2026-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2026-01-01 2026-06-30 0001498403 ifrs-full:CapitalReserveMember 2026-01-01 2026-06-30 0001498403 ifrs-full:WarrantsMember 2026-01-01 2026-06-30 0001498403 ifrs-full:SharePremiumMember 2026-01-01 2026-06-30 0001498403 ifrs-full:IssuedCapitalMember 2026-01-01 2026-06-30 0001498403 2026-06-30 0001498403 ifrs-full:RetainedEarningsMember 2026-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2026-06-30 0001498403 ifrs-full:CapitalReserveMember 2026-06-30 0001498403 ifrs-full:WarrantsMember 2026-06-30 0001498403 ifrs-full:SharePremiumMember 2026-06-30 0001498403 ifrs-full:IssuedCapitalMember 2026-06-30 0001498403 2025-06-30 0001498403 ifrs-full:RetainedEarningsMember 2025-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2025-06-30 0001498403 ifrs-full:CapitalReserveMember 2025-06-30 0001498403 ifrs-full:WarrantsMember 2025-06-30 0001498403 ifrs-full:SharePremiumMember 2025-06-30 0001498403 ifrs-full:IssuedCapitalMember 2025-06-30 0001498403 ifrs-full:NoncontrollingInterestsMember 2024-12-31 0001498403 ifrs-full:NoncontrollingInterestsMember 2025-01-01 2025-06-30 0001498403 ifrs-full:NoncontrollingInterestsMember 2025-06-30 0001498403 ifrs-full:NoncontrollingInterestsMember 2025-12-31 0001498403 ifrs-full:NoncontrollingInterestsMember 2026-01-01 2026-06-30 0001498403 ifrs-full:NoncontrollingInterestsMember 2026-06-30 0001498403 blrx:AmericanDepositarySharesMember blrx:HighbridgeCapitalManagementLlcMember 2024-11-01 2024-11-30 0001498403 blrx:PreFundedWarrantsMember blrx:HighbridgeCapitalManagementLlcMember 2024-11-01 2024-11-30 0001498403 blrx:AmericanDepositarySharesMember blrx:HighbridgeCapitalManagementLlcMember 2024-11-30 0001498403 blrx:PreFundedWarrantsMember blrx:HighbridgeCapitalManagementLlcMember 2024-11-30 0001498403 blrx:WarrantFourMember blrx:HighbridgeCapitalManagementLlcMember 2024-11-01 2024-11-30 0001498403 blrx:WarrantSixMember blrx:HighbridgeCapitalManagementLlcMember 2026-01-01 2026-06-30 0001498403 blrx:WarrantSixMember blrx:September2022OfferingMember 2026-06-30 0001498403 blrx:AmericanDepositarySharesMember blrx:January2025OfferingMember 2025-01-01 2025-01-31 0001498403 blrx:PreFundedWarrantsMember blrx:January2025OfferingMember 2025-01-01 2025-01-31 0001498403 blrx:AmericanDepositarySharesMember blrx:January2025OfferingMember 2025-01-31 0001498403 blrx:PreFundedWarrantsMember blrx:January2025OfferingMember 2025-01-31 0001498403 blrx:PlacementAgentMember blrx:PreFundedWarrantsMember blrx:January2025OfferingMember 2025-01-01 2025-01-31 0001498403 blrx:PlacementAgentMember blrx:PreFundedWarrantsMember blrx:January2025OfferingMember 2025-01-31 0001498403 blrx:WarrantFourMember blrx:January2025OfferingMember 2025-01-01 2025-01-31 0001498403 blrx:WarrantFourMember blrx:January2025OfferingMember 2025-01-31 0001498403 blrx:WarrantSixMember blrx:January2025OfferingMember 2026-01-01 2026-06-30 0001498403 blrx:WarrantSixMember blrx:January2025OfferingMember 2026-04-01 2026-06-30 0001498403 blrx:AmericanDepositarySharesMember blrx:September2022OfferingMember 2022-09-01 2022-09-30 0001498403 blrx:AmericanDepositarySharesMember blrx:April2024OfferingMember 2024-04-01 2024-04-30 0001498403 blrx:AmericanDepositarySharesMember blrx:September2022OfferingMember 2022-09-30 0001498403 blrx:AmericanDepositarySharesMember blrx:April2024OfferingMember 2024-04-30 0001498403 blrx:WarrantSixMember blrx:April2024OfferingMember 2026-01-01 2026-06-30 0001498403 blrx:WarrantSixMember blrx:September2022OfferingMember 2026-01-01 2026-06-30 0001498403 blrx:WarrantSixMember blrx:April2024OfferingMember 2024-04-01 2024-04-30 0001498403 blrx:WarrantFourMember blrx:September2022OfferingMember 2022-09-01 2022-09-30 0001498403 blrx:WarrantFourMember blrx:September2022OfferingMember 2022-09-30 0001498403 blrx:WarrantFourMember blrx:April2024OfferingMember 2024-04-01 2024-04-30 0001498403 blrx:WarrantFourMember blrx:April2024OfferingMember 2024-04-30 0001498403 blrx:HcwMember 2026-06-30 0001498403 blrx:HcwMember 2026-01-01 2026-06-30 0001498403 blrx:AssetTransferAgreementMember blrx:HemispherianAsMember blrx:TetragonMember 2025-09-01 2025-09-30 0001498403 blrx:AssetTransferAgreementMember blrx:HemispherianAsMember blrx:TetragonMember 2025-09-30 0001498403 blrx:AssetTransferAgreementMember blrx:HemispherianAsMember blrx:TetragonMember 2026-06-30 0001498403 blrx:AssetTransferAgreementMember blrx:HemispherianAsMember blrx:TetragonMember 2025-06-30 0001498403 2026-04-01 2026-06-30 0001498403 2025-04-01 2025-06-30 0001498403 blrx:PreFundedWarrantsMember blrx:DefinitiveAgreementInstitutionalInvestorMember 2026-08-01 2026-08-27 0001498403 blrx:PreFundedWarrantsMember blrx:DefinitiveAgreementInstitutionalInvestorMember 2026-08-27 0001498403 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2025-12-31 0001498403 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2026-06-30 0001498403 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:AtFairValueMember 2026-01-01 2026-06-30 iso4217:ILS pure shares iso4217:USD iso4217:USD shares blrx:Warrant 0001498403 false --12-31 Q2 6-K 2026 001-35223 BioLineRx Ltd. 2 HaMa’ayan Street Modi’in 7177871 IL 2026-06-30

3250000

4627000

17626000

8451000

201000

376000

456000

728000

2148000

2167000

23681000

16349000

160000

130000

696000

673000

16368000

16328000

17224000

17131000

40905000

33480000

4479000

3493000

4294000

1743000

2206000

234000

280000

2174000 2420000

12123000

13679000

4460000

2220000

977000

962000

5437000

3182000

17560000

16861000

73428000

73776000

327584000

327928000

3686000 3686000

15916000

15425000

-1416000

-401002000

-405629000

18196000

13770000

5149000

2849000

23345000

16619000

40905000

33480000

304000

294000

559000

771000

72000

59000

106000

154000

232000

235000

453000

617000

2326000

2943000

3949000

5471000

209000

865000

1198000

1723000

-2303000

-3573000

-4694000

-6577000

-1851000 -690000 5793000 -232000

490000

132000

784000

340000

276000

208000

696000

458000

-3940000

-4339000

1187000

-6927000

-3940000

-3026000

1187000

-4627000

-1313000

-2300000

-3940000

-4339000

1187000

-6927000

-0

2369687536

2664807584

2294127662

2662530811

1336670

38097000

353693000

5367000

17547000

-1416000

-399827000

13461000

925137 25664000 -20988000 501000 0 0 0 0 5177000 295804 8058000 -5876000 -2182000 0 0 0 0 0 0 646000 0 -646000 0 0 0 0

247000

1187000

2557611

71819000

327475000

3686000

17148000

-1416000

-398640000

20072000

2610814

73428000

327584000

3686000

15916000

-1416000

-401002000

5149000

23345000

10163 348000 -304000 0 0 0 0 0 44000 0 648000 0 -648000 0 0 0 0

157000

-4627000

-2300000

-6927000

2620977

73776000

327928000

3686000

15425000

-1416000

-405629000

2849000

16619000

1187000

-6927000

-3955000

1430000

-2768000

-5497000

-24818000

-7663000

-12926000 -16714000

11000

-11881000

9051000

13554000

44000

2240000

262000

124000

11052000

-2320000

-3597000

1234000

10436000

3250000

350000

143000

7189000

4627000

341000

166000

-350000

-143000

-6410000

246000

247000

157000

48000 124000 702000 0 110000 82000 -5312000 632000

2398000

-1146000 447000

295000

-19000

-2482000

1264000

1357000 798000

-3955000

1430000

583000 463000 694000 467000 45000 73000

<div> NOTE 1 – GENERAL INFORMATION <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:19.85pt">a.</td> <td style="text-align:justify">General</td> </tr> </table> BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development (primarily in clinical stages) and commercialization of therapeutics, with a focus on the fields of oncology and hematology. The Company’s American Depositary Shares (“ADSs”) are traded on the NASDAQ Capital Market, and its ordinary shares are traded on the Tel Aviv Stock Exchange. Each ADS represents 600 ordinary shares. The Company has one wholly owned subsidiary, BioLineRx USA, Inc., incorporated in the U.S., which had been engaged in commercialization activities associated with the launch of motixafortide for stem-cell mobilization in the U.S., and which is now substantially inactive since the end of 2024 (see below). In addition, the Company is the controlling shareholder of Tetragon Biosciences Ltd. (“Tetragon”), a company incorporated in Israel in September 2025 for the development and commercialization of GLIX1, a clinical-stage, first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers (see Note 8). In September 2023, the U.S. Food and Drug Administration (“FDA”) approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S. In October 2023, the Company out-licensed the rights to motixafortide for all indications in substantially all of Asia, and in November 2024, the Company out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors. In connection with the November 2024 transaction, the Company shut down its independent commercialization activities in the U.S., and entered into an agreement to repay a substantial portion of its outstanding debt, as well as restructure the remaining debt balance. Following these actions, the Company refocused its operations on development activities in Israel in the fields of oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate. <div></div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:19.85pt">b.</td> <td style="text-align:justify">War in Israel</td> </tr> </table> On October 7, 2023, an unprecedented invasion was launched against Israel from the Gaza Strip by terrorists from the Hamas terrorist organization that infiltrated Israel’s southern border and other areas within the country, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli civilian population. These attacks resulted in extensive deaths, injuries and the kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas, with commencement of a military campaign against the terrorist organization, in parallel to its continued rocket and terror attacks. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement controlling parts of Yemen, and with Iran. It is also possible that other terrorist organizations, including Palestinian military organizations in the West Bank, will join the hostilities. On October 9, 2025, Israel, Hamas, the US, and other counties in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas. In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran’s nuclear program and military commanders. While a ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading Iran’s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population centers and military installations in Israel, Europe and neighboring countries in the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region. A temporary ceasefire was brokered in April 2026 to allow the parties to negotiate, but its durability and the prospects for a successful agreement remain uncertain. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business, financial condition and results of operations. The length and severity of the current conflicts in Gaza, Lebanon, Iran and the broader region is unknown at this time, and there can be no assurance that certain ceasefires will hold or that military activities and hostilities will not continue to exist at varying levels of intensity. Any or all of these situations may potentially escalate in the future to more violent events or a greater regional conflict. The Company’s headquarters and principal development operations are located in the State of Israel. In addition, all of its key employees, officers and directors are residents of Israel. The ongoing war and other hostilities in Israel have not, to date, materially impacted the Company’s business or operations. Nevertheless, since these are events beyond the Company’s control, their continuation or cessation may affect the Company’s operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees. <div></div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:49.6pt"></td> <td style="width:21.25pt">c.</td> <td style="text-align:justify">Going concern</td> </tr> </table> The Company has incurred accumulated losses in the amount of $406 million through June 30, 2026, and it expects to continue incurring losses and negative cash flows from operations until the cash flows from its strategic partnerships reach a level to offset its ongoing development costs. In this regard, Company management monitors rolling forecasts of the Company’s liquidity reserves on the basis of anticipated cash flows and seeks to maintain liquidity balances at levels that are sufficient to meet its needs. Management believes that the Company’s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027. The Company’s cash flow projections are subject to various risks and uncertainties concerning their fulfilment, and these factors and the risks inherent in the Company’s operations indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) on the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the realization of capital inflows from its strategic partnerships and, if and when required, raising capital through the issuance of debt or equity securities. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in realizing the potential cash flows from its strategic partnerships and/or in raising capital, it may need to reduce activities, or curtail or cease operations. <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:49.6pt"></td> <td style="width:21.25pt">d.</td> <td style="text-align:justify">Approval of financial statements</td> </tr> </table> The unaudited condensed consolidated interim financial statements of the Company as of June 30, 2026, and for the three and six months then ended, were approved by the Board of Directors on August 28, 2026, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer. </div>

600

-406000000

<div> NOTE 2 – BASIS OF PREPARATION The Company’s condensed consolidated interim financial statements as of June 30, 2026 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair presentation of financial position, results of operations, changes in equity and cash flows in conformity with IFRS® Accounting Standards as issued by the International Accounting Standards Board (“IASB®”) (hereinafter, “IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2025 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company’s accounting policies. These inputs also consider, among other things, the implications of pandemics and wars across the globe (including the current conflicts in the Middle East) on the Company’s activities, and the resulting effects on critical and significant accounting estimates, most significantly in relation to the impairment of indefinite-lived intangible assets. In this regard, U.S. and global markets are currently experiencing volatility and disruption following the escalation of geopolitical tensions. As of the date of release of these financial statements, the Company estimates there are no material effects of those geopolitical tensions on its financial position and results of operations. </div>

<div> NOTE 3 – MATERIAL ACCOUNTING POLICIES <div> <div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">a.</td> <td style="text-align:justify">General </td> </tr> </table> The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2025 and for the year then ended. </div> </div> <div></div> <div> <div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">b.</td> <td style="text-align:left">New international financial reporting standards, amendments to standards and new interpretations </td> </tr> </table> IFRS 18, Presentation and Disclosure in the Financial Statements This standard replaces the international accounting standard IAS 1, “Presentation of Financial Statements.” As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investing and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (“non-GAAP measures”), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements. IFRS 18 is effective for annual reporting periods beginning on or after January 1, 2027. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures. </div> </div> </div>

<div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">a.</td> <td style="text-align:justify">General </td> </tr> </table> The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2025 and for the year then ended. </div> <div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">b.</td> <td style="text-align:left">New international financial reporting standards, amendments to standards and new interpretations </td> </tr> </table> IFRS 18, Presentation and Disclosure in the Financial Statements This standard replaces the international accounting standard IAS 1, “Presentation of Financial Statements.” As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investing and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (“non-GAAP measures”), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements. IFRS 18 is effective for annual reporting periods beginning on or after January 1, 2027. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures. </div> <div> NOTE 4 – AT-THE-MARKET (“ATM”) SALES AGREEMENT WITH HCW The Company maintains an ATM facility with H.C. Wainwright & Co., LLC (“HCW”) pursuant to an ATM sales agreement entered into in September 2021. In accordance with the agreement, the Company is entitled, at its sole discretion, to offer and sell through HCW, acting as a sales agent, ADSs having an aggregate offering price of up to $25.0 million throughout the period during which the ATM facility remains in effect. The Company has agreed to pay HCW a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. During the six months ended June 30, 2026, 16,938 ADSs were issued from the facility. From the effective date of the agreement through the issuance date of this report, 841,948 ADSs have been sold under the program for total net proceeds of $9.3 million. </div> 25000000 0.03 16938 841948 9300000 <div> NOTE 5 – FINANCINGS <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">a.</td> <td style="text-align:left">September 2022 offering</td> </tr> </table> In September 2022, the Company completed a registered direct offering of 340,909 ADSs at a price of $44.00 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 340,909 ADSs. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $46.00 per ADS. In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 17,045 ADSs. These warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $55.00 per ADS. Gross proceeds from the offering totaled $15.0 million, with net proceeds of $13.5 million, after deducting fees and expenses. The offering consideration allocated to the placement agent warrants amounted to $0.4 million. The warrants issued to the investors have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 3.62%, and an average standard deviation of 82.5%. The gross consideration initially allocated to the investor warrants amounted to $9.1 million, with total issuance costs initially allocated to the warrants amounting to $0.8 million. The fair value of the ordinary warrants was immaterial as of June 30, 2026, and was based on the then current price of an ADS, a risk-free interest rate of 4.06%, an average standard deviation of 74.8%, and on the remaining contractual life of the ordinary warrants. The changes in fair value for the three and six months ended June 30, 2026, which were immaterial, have been recorded as non-operating income in the statement of comprehensive income (loss). As of June 30, 2026, 63,636 of these warrants had been exercised. The placement agent warrants have been classified in shareholders’ equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants. <div></div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">b.</td> <td style="text-align:left">April 2024 offering </td> </tr> </table> In April 2024, the Company completed a registered direct offering of 187,500 ADSs at a price of $32.00 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 187,500 ADSs. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $32.00 per ADS. Gross proceeds from the offering totaled $6.0 million, with net proceeds of $5.4 million, after deducting fees and expenses. The warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The fair value of the warrants is computed using the Black-Scholes option pricing model and is determined by using a level 3 valuation technique. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.21%, and an average standard deviation of 84.7%. The fair value initially allocated to the investor warrants amounted to $6.3 million, with total issuance costs initially allocated to the warrants amounting to $0.6 million. Due to a difference between the fair value at initial recognition and the transaction price (“day 1 loss”), upon initial recognition, the fair value of the warrants was adjusted by the amount of $0.3 million, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life. The fair value of the ordinary warrants amounted to $0.2 million as of June 30, 2026, and was based on the then current price of an ADS, a risk-free interest rate of 4.15%, an average standard deviation of 93.4%, and on the remaining contractual life of the ordinary warrants. The changes in fair value for the three and six months ended June 30, 2026, which were immaterial, have been recorded as non-operating expenses in the statement of comprehensive income (loss). As of June 30, 2026, none of these warrants had been exercised. <div></div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">c.</td> <td style="text-align:left">Securities purchase agreement – Highbridge</td> </tr> </table> In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Management LLC (“Highbridge”) of 103,037 ADSs and 308,749 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $21.86 and $21.85, respectively. The Company also issued to the investors unregistered ordinary warrants to purchase an aggregate of 205,893 ADSs. Gross proceeds from the offering totaled $9.0 million, with net proceeds of $8.9 million, after deducting fees and expenses. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire four years from the date of issuance, and have an exercise price of $23.60 per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the outstanding share capital of the Company immediately after giving effect to such exercise. The ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The pre-funded warrants have been classified in shareholders’ equity, with initial recognition at fair value on the date issued, using the same assumptions as the ordinary warrants. The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.19%, and an average standard deviation of 84.5%. The gross consideration initially allocated to ordinary warrants amounted to $2.7 million, with total issuance costs initially allocated to the ordinary warrants amounting to an immaterial amount. The fair value of the ordinary warrants amounted to $0.1 million as of June 30, 2026, and was based on the then current price of an ADS, a risk-free interest rate of 4.15%, an average standard deviation of 96.1%, and on the remaining contractual life of the ordinary warrants. The changes in fair value for the three and six months ended June 30, 2026, which were immaterial, have been recorded as non-operating income in the statement of comprehensive income (loss). During the six months ended June 30, 2026, none of the pre-funded warrants were exercised, and none of the ordinary warrants were exercised. <div></div> <table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"> <tr style="vertical-align:top"> <td style="width:51.05pt"></td> <td style="width:18pt">d.</td> <td style="text-align:left">January 2025 offering</td> </tr> </table> In January 2025, the Company completed a registered direct offering to certain institutional investors of 858,303 ADSs and 391,697 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $8.00 and $7.996, respectively. The Company also issued to investors in the offering unregistered ordinary warrants to purchase an aggregate of 1,250,000 ADSs. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire five years from the date of issuance, and have an exercise price of $8.00 per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder) of the outstanding share capital of the Company immediately after giving effect to such exercise. In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 62,500 ADSs. These warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $10.00 per ADS. The offering consideration allocated to the placement agent warrants amounted to $0.5 million. Gross proceeds from the offering totaled $10.0 million, with net proceeds of $8.9 million, after deducting fees and expenses. The investors’ ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The pre-funded warrants have been classified in shareholders’ equity. The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model and is determined by using a level 3 valuation technique. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.41%, and an average standard deviation of 90.2%. The fair value initially allocated to the investor ordinary warrants amounted to $10.4 million, with total issuance costs initially allocated to the ordinary warrants amounting to $0.7 million. Due to a difference between the fair value at initial recognition and the transaction price (“day 1 loss”), upon initial recognition, the fair value of the ordinary warrants was adjusted by the amount of $1.4 million, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life. The fair value of the ordinary warrants amounted to $2.1 million as of June 30, 2026, and was based on the then current price of an ADS, a risk-free interest rate of 4.17%, an average standard deviation of 90.7%, and on the remaining contractual life of the warrants. The changes in fair value for the three and six months ended June 30, 2026, amounting to $0.7 million and $0.3 million, respectively, have been recorded as a non-operating expenses in the statement of comprehensive income (loss). <div></div> As of June 30, 2026, all of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised. The placement agent warrants have been classified in shareholders’ equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants. </div> 340909 44 340909 five years 46 17045 five years

15000000 13500000 400000

0.0362

0.825

9.1

800000

0.0406

0.748

63636

187500 32 187500 five years 32 6000000 5400000

0.0421

0.847

6.3

600000

0.3

0.2

0.0415

0.934

103037 308749 21.86 21.85 205893 9000000 8900000

0.004

four years 23.6 0.0499

0.0419

0.845

2.7

0.1

0.0415

0.961

858303 391697 8 7.996 1250000

0.004

five years 8 0.0499 62500 five years 10 500000 10000000 8900000

0.0441

0.902

10400000

700000 1400000

2100000

0.0417

0.907

0.7 0.3

NOTE 6 – FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) <div style="margin-left:45pt"> <table cellpadding="0" cellspacing="0" style="border-collapse:separate;font:10pt Times New Roman, Times, serif;width:88.5%"> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid">Warrants</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:right"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid">in USD thousands</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="width:88%;font-weight:bold;text-align:left;padding-bottom:1pt">Balance as of December 31, 2025</td> <td style="width:1%;padding-bottom:1pt"> </td> <td style="width:1%;border-bottom:Black 1pt solid;text-align:left"> </td> <td style="width:9%;border-bottom:Black 1pt solid;text-align:right">2,174</td> <td style="width:1%;padding-bottom:1pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="font-weight:bold;text-align:left">Changes during 2026:</td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:left;padding-bottom:1pt;padding-left:15.95pt">Changes in fair value through profit and loss</td> <td style="padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;text-align:right">246</td> <td style="padding-bottom:1pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="font-weight:bold;text-align:left;padding-bottom:2.5pt">Balance as of June 30, 2026</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,420</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> </table> </div>

<div style="margin-left:45pt"> <table cellpadding="0" cellspacing="0" style="border-collapse:separate;font:10pt Times New Roman, Times, serif;width:88.5%"> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid">Warrants</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:right"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid">in USD thousands</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="width:88%;font-weight:bold;text-align:left;padding-bottom:1pt">Balance as of December 31, 2025</td> <td style="width:1%;padding-bottom:1pt"> </td> <td style="width:1%;border-bottom:Black 1pt solid;text-align:left"> </td> <td style="width:9%;border-bottom:Black 1pt solid;text-align:right">2,174</td> <td style="width:1%;padding-bottom:1pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="font-weight:bold;text-align:left">Changes during 2026:</td> <td> </td> <td style="text-align:left"> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:left;padding-bottom:1pt;padding-left:15.95pt">Changes in fair value through profit and loss</td> <td style="padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;text-align:left"> </td> <td style="border-bottom:Black 1pt solid;text-align:right">246</td> <td style="padding-bottom:1pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="font-weight:bold;text-align:left;padding-bottom:2.5pt">Balance as of June 30, 2026</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:left"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,420</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> </table> </div>

2174000 246000 2420000

<div> <div> NOTE 7 – SHAREHOLDERS’ EQUITY As of December 31, 2025 and June 30, 2026, the Company’s share capital is composed of ordinary shares, as follows: </div> <div style="line-height:1.25"> </div> <div> <div> <div style="margin-left:70pt"> <table cellpadding="0" cellspacing="0" style="border-collapse:separate;font:10pt Times New Roman, Times, serif;width:90.5%"> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="4" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid">Number of ordinary shares</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">December 31,</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">June 30,</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2026</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td> </td> <td> </td> <td style="text-align:right"> </td> <td> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="width:78%;padding-bottom:2.5pt">Authorized share capital</td> <td style="width:1%;padding-bottom:2.5pt"> </td> <td style="width:9%;border-bottom:Black 2.5pt double;text-align:right">20,000,000,000</td> <td style="width:1%;padding-bottom:2.5pt;text-align:left"> </td> <td style="width:1%;padding-bottom:2.5pt"> </td> <td style="width:9%;border-bottom:Black 2.5pt double;text-align:right">20,000,000,000</td> <td style="width:1%;padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:left;padding-bottom:2.5pt">Issued and paid-up share capital</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,610,814,390</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,620,977,190</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="4" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right"> In USD and NIS </td> <td style="padding-bottom:1pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right"> December 31, </td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right"> June 30, </td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2026</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:left;padding-bottom:2.5pt">Authorized share capital (in NIS)</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,000,000,000</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,000,000,000</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:left;padding-bottom:2.5pt">Issued and paid-up share capital (in NIS)</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">261,081,439</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">262,097,719</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:left;padding-bottom:2.5pt">Issued and paid-up share capital (in USD)</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">73,428,375</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">73,776,416</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> </table> </div> </div> </div> </div>

<div> <div style="margin-left:70pt"> <table cellpadding="0" cellspacing="0" style="border-collapse:separate;font:10pt Times New Roman, Times, serif;width:90.5%"> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="4" style="font-weight:bold;text-align:center;border-bottom:Black 1pt solid">Number of ordinary shares</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">December 31,</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">June 30,</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2026</td> <td style="padding-bottom:1pt;font-weight:bold"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td> </td> <td> </td> <td style="text-align:right"> </td> <td> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="width:78%;padding-bottom:2.5pt">Authorized share capital</td> <td style="width:1%;padding-bottom:2.5pt"> </td> <td style="width:9%;border-bottom:Black 2.5pt double;text-align:right">20,000,000,000</td> <td style="width:1%;padding-bottom:2.5pt;text-align:left"> </td> <td style="width:1%;padding-bottom:2.5pt"> </td> <td style="width:9%;border-bottom:Black 2.5pt double;text-align:right">20,000,000,000</td> <td style="width:1%;padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:left;padding-bottom:2.5pt">Issued and paid-up share capital</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,610,814,390</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,620,977,190</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td colspan="4" style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right"> In USD and NIS </td> <td style="padding-bottom:1pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right"> December 31, </td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:right"> June 30, </td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="padding-bottom:1pt"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2025</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> <td style="font-weight:bold;padding-bottom:1pt"> </td> <td style="border-bottom:Black 1pt solid;font-weight:bold;text-align:center">2026</td> <td style="padding-bottom:1pt;font-weight:bold;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:left;padding-bottom:2.5pt">Authorized share capital (in NIS)</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,000,000,000</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">2,000,000,000</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> <td> </td> <td style="text-align:right"> </td> <td style="text-align:left"> </td> </tr> <tr style="vertical-align:bottom"> <td style="text-align:left;padding-bottom:2.5pt">Issued and paid-up share capital (in NIS)</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">261,081,439</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">262,097,719</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255)"> <td style="text-align:left;padding-bottom:2.5pt">Issued and paid-up share capital (in USD)</td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">73,428,375</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> <td style="padding-bottom:2.5pt"> </td> <td style="border-bottom:Black 2.5pt double;text-align:right">73,776,416</td> <td style="padding-bottom:2.5pt;text-align:left"> </td> </tr> </table> </div> </div>

20000000000

2610814390

2620977190

2000000000 2000000000 261081439 262097719 73428375 73776416 <div> <div> NOTE 8 – AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 In September 2025, the Company entered into a collaboration transaction with Hemispherian AS, a Norwegian corporation (“Hemispherian”), for the development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors. As part of the transaction, (i) the Company and Hemispherian entered into a Collaboration and Shareholders Agreement (the “Agreement with Hemispherian”), which governs the ownership, governance, funding, administration, and related operational and commercial terms of a new company (Tetragon) established by the Company and Hemispherian, and (ii) Hemispherian and Tetragon entered into an Asset Transfer Agreement (the “ATA”), pursuant to which Hemispherian transferred to Tetragon certain intellectual property, regulatory filings, know-how, and related assets primarily in respect of GLIX1, Hemispherian’s lead compound (the “Transferred Assets”). In consideration for the transfer of the Transferred Assets, Hemispherian received 60% of the issued share capital of Tetragon. In consideration for the Company’s commitment to invest $5 million in Tetragon (the “Threshold Amount”) within 36 months as of the date of the Agreement with Hemispherian, the Company received 40% of the issued share capital of Tetragon. Such threshold amount is to be paid in tranches according to a development plan, and the 36-month period may be extended by an additional six months upon the occurrence of certain events as specified in the Agreement with Hemispherian (the “Threshold Term”). If the Company does not invest the full Threshold Amount by the end of the Threshold Term, Hemispherian will have the right to repurchase, for nominal consideration, a pro rata portion of the Company’s shares in Tetragon corresponding to the unfunded portion of the Threshold Amount. As of June 30, 2026, the Company had invested $4.5 million of the Threshold Amount ($5.2 million as of the approval date of these financial statements). Following the investment of the Threshold Amount, the Company may make additional investments in Tetragon. For each incremental $1 million invested by the Company beyond the Threshold Amount, the Company will be entitled to an additional 1% equity interest, up to an aggregate maximum ownership of 70%. Following the attainment of a 50% stake by the Company in Tetragon, Hemispherian will have the right to co-invest alongside the Company on the same terms in order to maintain a 50% ownership stake in Tetragon. Furthermore, under the terms of the Agreement with Hemispherian, the Company is responsible for managing and implementing Tetragon’s activities and overseeing its operations, budget, and expenses. Following the closing, Tetragon began to pay Hemispherian a monthly advisory fee of $80,000 for a period of 24 months or until the termination of the collaboration, whichever occurs first. The Agreement with Hemispherian provides for the establishment of a board of directors of Tetragon as well as a steering committee with joint representation from both the Company and Hemispherian. The Company holds the deciding vote in the event of any deadlock on either of such corporate bodies and, accordingly, is the controlling shareholder of Tetragon. Tetragon has a first-look right, as well as a right of first refusal, on other assets in Hemispherian’s pipeline for defined periods specified in the ATA. The ATA and the Agreement with Hemispherian contain customary representations and warranties, indemnification and other provisions customary for transactions of this nature. The ATA and Agreement with Hemispherian also include termination events, including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of Tetragon to operate due to insufficient financial resources. In connection with the ATA and Agreement with Hemispherian, an intangible asset in the amount of $6.0 million was recorded in respect of the GLIX1 molecule at fair value, against a minority interest in the same amount. </div> </div> 0.60

5000000

0.40

4500000

5200000

1000000 0.01

0.70

0.50 0.50 80000

6000000

<div> NOTE 9 – SUBSEQUENT EVENT On August 27, 2026, the Company entered into a definitive agreement with an institutional investor for the issuance of 1,348,921 ADSs or ADS equivalents (pre-funded warrants) at a purchase price of $2.78 per ADS or ADS equivalent, via a registered direct offering. In addition, the Company will issue to the investor unregistered ordinary warrants to purchase up to an aggregate of 2,023,382 ADSs or ADS equivalents via a concurrent private placement. The warrants will have an exercise price of $2.78 per share and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about August 31, 2026, subject to the satisfaction of customary closing conditions. Gross proceeds from the offering are $3.75 million, before deducting the placement agent fees and other offering expenses payable by the Company. The offering purchase agreement includes lock-up, warranty, indemnification, and other provisions customary for transactions of this nature. In connection with the offering, the Company entered into a warrant amendment pursuant to which the Company agreed to amend certain outstanding ordinary warrants to purchase 277,273 ADSs previously issued and held by the investor. The amended warrants will have a reduced exercise price of $2.78 per share, and an extended expiration date through August 31, 2031. </div>

1348921 2.78 2023382

2.78

five years

3750000

277273

2.78